Results 71 to 80 of about 838,442 (361)

Identifying transcription factors controlling the basal expression of human MRP4 highlights a substantial role for Sp1

FEBS Open Bio, EarlyView.
The MRP4 transporter exports several drugs and signaling molecules. Here, we identified key promoter elements regulating basal MRP4 expression. Using reporter assays, we defined a conserved region with essential Sp1 and contributory Ets sites, which controlled basal MRP4 expression.
Debora Singer, Angelique Kragl, Katrin Ziems, Juliane Glaubitz, Sophie Grammbauer, Susanne Hildebrandt, Mladen V. Tzvetkov, Gabriele Jedlitschky   +7 more
wiley   +1 more source

Overexpression of the protein kinase CK2 increases the survival and resistance to chemotherapy of acute myeloid leukemia cells [PDF]

, 2013
Background: The critical role of protein kinase CK2 in the regulation of cellular apoptosis suggests its may be involvement in tumor cell resistance to both conventional and unconventional therapies.
PAVAN, LAURA
core  

Treatment of Relapsed Acute Myeloid Leukemia

Current Treatment Options in Oncology, 2020
Relapse is still a common scenario in acute myeloid leukemia (AML) treatment and occurs in 40–50% of younger and the great majority of elderly patients. The prognosis in relapsed AML patients is generally poor but depends largely on the timing of relapse
F. Thol, A. Ganser
semanticscholar   +1 more source

Chronic Myeloid Leukemia in 2007 [PDF]

Journal of Managed Care Pharmacy, 2007
Chronic myeloid leukemia (CML), a hematopoietic stem cell cancer representing 15-20% of adult leukemias, is discussed. Epidemiology, staging biology, and monitoring techniques are reviewed.CML is a myeloproliferative disorder that affects all lineages of hematopoiesis.
openaire   +3 more sources

One size does not fit all: An in vitro evaluation of the effects of bezafibrate and medroxyprogesterone acetate on human SH‐SY5Y and U‐87 MG cancer cells

FEBS Open Bio, EarlyView.
Drugs previously repurposed to target blood cancers reduced neuroblastoma and glioblastoma cell growth and viability. However, their levels of anticancer activity were different and their clinical application may be problematic due to side effects at effective doses.
Abhishek Kharawatkar, Francesco Michelangeli, Farhat Latif Khanim, Christopher Martin Bunce, William Eustace Basil Johnson   +4 more
wiley   +1 more source

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group

Haematologica, 2018
Assessment of minimal residual disease has emerged as a powerful prognostic factor in acute myeloid leukemia. In this study, we investigated the potential of IDH1/2 mutations as targets for minimal residual disease assessment in acute myeloid leukemia ...
Yann Ferret, Nicolas Boissel, Nathalie Helevaut, Jordan Madic, Olivier Nibourel, Alice Marceau-Renaut, Maxime Bucci, Sandrine Geffroy, Karine Celli-Lebras, Sylvie Castaigne, Xavier Thomas, Christine Terré, Hervé Dombret, Claude Preudhomme, Aline Renneville   +14 more
doaj   +1 more source

From energy provision to protein synthesis: Tunnelling nanotubes as mediators of intercellular metabolic cooperation in cancer

FEBS Open Bio, EarlyView.
The cytoskeleton‐mediated transport of mitochondria via tunnelling nanotubes restores respiration, increases ATP production, rescues cells from apoptosis, activates the AKT/mTOR signalling pathway, promotes cell migration and invasiveness, contributes to cancer progression and treatment resistance.
Stanislava Martínková, Jan Trnka
wiley   +1 more source

A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1)

Haematologica, 2008
Acute myeloid leukemia with mutated NPM1 gene and aberrant cytoplasmic expression of nucleophosmin (NPMc+ acute myeloid leukemia) shows distinctive biological and clinical features.
Arcangelo Liso, Filippo Castiglione, Antonio Cappuccio, Fabrizio Stracci, Richard F. Schlenk, Sergio Amadori, Christian Thiede, Susanne Schnittger, Peter J.M. Valk, Konstanze Döhner, Massimo F. Martelli, Markus Schaich, Jürgen Krauter, Arnold Ganser, Maria P. Martelli, Niccolò Bolli, Bob Löwenberg, Torsten Haferlach, Gerhard Ehninger, Franco Mandelli, Hartmut Döhner, Franziska Michor, Brunangelo Falini   +22 more
doaj   +1 more source

Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse

, 2012
This report describes the clinical courses of two acute myeloid leukemia patients. Both had MLL translocations, the first a t(10;11)(p11.2;q23) with MLL-AF10 and the second a t(11;19)(q23;p13.1) with MLL-ELL fusion.
Meyer, Claus, Carola Tietze-Bürger, Claus Meyer, Igor Blau, Burmeister, Thomas, Molkentin, Mara, Thomas Burmeister, Mara Molkentin, Nils Lachmann, Uharek, Lutz, Rolf Marschalek, Tietze-Bürger, Carola, Friedrichs, Birte, Blau, Igor Wolfgang, Jörg Beyer, Marschalek, Rolf, Schwartz, Stefan, Lutz Uharek, Beyer, Jörg, Stefan Schwartz, Gunnar Lohm, Birte Friedrichs, Lachmann, Nils, Lohm, Gunnar   +23 more
core   +1 more source

Exploring downstream pathways of aberrantly activated kinases for targeted leukemia therapy [PDF]

, 2008
Genetic alterations resulting in uncontrolled protein tyrosine kinases (PTKs) activity are frequently found in leukemia and in human solid cancers. Although the development of small molecule kinase inhibitors has revolutionized therapy for PTKinduced ...
Gasser, Christelle
core   +1 more source